First FDA Breakthrough Therapy Designation in PSMA PET Imaging Granted to Cu-64 SAR-bisPSMA in Biochemical Recurrence of Prostate Cancer

Clarity Pharmaceuticals announced that the US FDA granted ⁶⁴Cu-SAR-bisPSMA Breakthrough Therapy designation for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer with suspected recurrence based on elevated serum prostate-specific antigen level.